Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
186
resultados
Última actualización
12/03/2026 [08:23:00]
Resumen de: AU2024265914A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Resumen de: WO2024227011A1
Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.
Resumen de: MX2025014639A
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Resumen de: AU2026201149A1
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn’s disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and 5 kits for predicting the response to the therapy of the inflammatory bowel disease. eb e b
Resumen de: US20260060660A1
The present disclosure provides improved methods of processing a fecal sample by a human subject in which the fecal sample is collected at home and subsequently delivered to a medical diagnostics laboratory. As described herein, the means of collecting and processing the fecal sample can desirably reduce the number of steps undertaken by the human subject, including avoiding steps of removing or separating the fecal sample into multiple portions. Furthermore, the human subject does not have to perform an immunological test (e.g., a fecal immunochemical test (FIT) or an immunochemical fecal occult blood test (iFOBT)) at home.
Resumen de: WO2026047225A1
Provided herein are agents and methods suitable for the treatment of inflammatory diseases of the intestine. For instance, agents and methods are provided for the treatment of inflammatory bowel disease, Crohn's disease, ulcerative colitis, Celiac disease, and colitis-associated colorectal cancer.
Resumen de: WO2026050646A1
This disclosure concerns metabolites that can be used to identify and characterize inflammatory bowel disease (IBD) as well as assess treatment for IBD.
Resumen de: WO2026050626A1
The present disclosure provides improved methods of processing a fecal sample by a human subject in which the fecal sample is collected at home and subsequently delivered to a medical diagnostics laboratory. As described herein, the means of collecting and processing the fecal sample can desirably reduce the number of steps undertaken by the human subject, including avoiding steps of removing or separating the fecal sample into multiple portions. Furthermore, the human subject does not have to perform an immunological test (e.g., a fecal immunochemical test (FIT) or an immunochemical fecal occult blood test (iFOBT)) at home.
Resumen de: US20260055183A1
Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.
Resumen de: US20260057960A1
Disclosed herein are methods and systems for administering therapy to subjects who have been determined to display or not display a gene expression response signature established to distinguish between responsive and non-responsive prior subjects who have received the therapy. The subject and prior subjects may suffer from a disease, disorder, or condition for which it is desired to predict whether the subject will respond to the therapy. In an aspect, the disease, disorder, or condition may be an autoimmune disorder such as ulcerative colitis. The subject may be administered an anti-TNF therapy or an alternative to anti-TNF therapy based upon predictions provided by methods and systems described herein.
Resumen de: US20260053426A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: AU2024260758A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: US2024254217A1
The present disclosure generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.
Resumen de: WO2026034527A1
Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and/or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.
Resumen de: CN120958131A
Provided herein are methods for treating or preventing pouch inflammation comprising administering a SMAD7 antisense oligonucleotide or a pharmaceutical formulation comprising the SMAD7 antisense oligonucleotide.
Resumen de: WO2024206308A2
Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.
Resumen de: US2025277269A1
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: WO2026027669A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Resumen de: US20260036584A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: WO2026027676A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Resumen de: MX2025014639A
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Resumen de: MX2025014639A
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Resumen de: AU2024283890A1
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Nº publicación: WO2026024847A2 29/01/2026
Solicitante:
BAYLOR UNIV [US]
BAYLOR UNIVERSITY
Resumen de: WO2026024847A2
Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.
BOPI
Sede Electrónica
